Actively Recruiting
Phase 2 Study of Immunotherapy With or Without Particle Beam Radiation Therapy for Advanced Hepatocellular Carcinoma with Vascular Invasion
Led by National Cancer Center, Korea · Updated on 2025-12-26
128
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of combining immunotherapy with radiotherapy compared to immunotherapy alone for patients with advanced hepatocellular carcinoma HCC that involves major blood vessels. This Phase II study focuses on patients with unresectable or metastatic disease showing major vascular invasion, aiming to improve treatment outcomes for this serious liver cancer. The trial includes two treatment groups one receiving immunotherapy combined with proton beam radiation therapy, and the other receiving immunotherapy alone. The radiation dose and schedule are tailored by physicians based on normal tissue safety. Participants receive these treatments concurrently as part of the study interventions. Participants will be monitored for progression-free survival over about three years along with other outcomes like overall survival, time to progression, and response rates. The study involves regular assessments including imaging to measure tumor response and safety evaluations. This helps researchers track both treatment effects and any side effects throughout the study period.
CONDITIONS
Brief Title
A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion
Research Team
Y
Yumi Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
